Logo image
Plasma cell proliferative index is an independent predictor of progression in smoldering multiple myeloma
Journal article   Open access   Peer reviewed

Plasma cell proliferative index is an independent predictor of progression in smoldering multiple myeloma

Mohammed A. Aljama, M. Hasib Sidiqi, Arjun Lakshman, Angela Dispenzieri, Dragan Jevremovic, Morie A. Gertz, Martha Q. Lacy, Francis K. Buadi, David Dingli, Eli Muchtar, …
Blood advances, v 2(22), pp 3149-3154
27 Nov 2018
PMID: 30463914
url
https://doi.org/10.1182/bloodadvances.2018024794View
Published, Version of Record (VoR) Open

Abstract

Lymphoid Neoplasia
PCPI identifies high-risk SMM. Patients with an elevated proliferative index have a shorter time to progression, independent of conventional risk models. The plasma cell proliferative index (PCPI), determined by a slide technique or by flow cytometry, detects cells in the S phase of the cell cycle and is a useful prognostic tool in patients with plasma cell disorders such as multiple myeloma and amyloidosis. We conducted a retrospective review analyzing the prognostic effect of PCPI in 306 patients with smoldering multiple myeloma (SMM). Seventy-nine (26%) patients had an elevated PCPI (>0.5). An elevated PCPI predicted an inferior time to progression (median, 3.0 vs 7.1 years for those with a low PCPI; P = .0004). Within 24 months, the progression rate was significantly higher for patients with an elevated PCPI (49% vs. 20%; P < .0001). PCPI is a valuable tool in risk stratifying patients with SMM and identifies patients with earlier progression who may benefit from closer follow-up and consideration of early intervention trials.

Metrics

3 Record Views
27 citations in Scopus

Details

UN Sustainable Development Goals (SDGs)

This publication has contributed to the advancement of the following goals:

#3 Good Health and Well-Being

InCites Highlights

Data related to this publication, from InCites Benchmarking & Analytics tool:

Web of Science research areas
Hematology
Logo image